INTRODUCTION

M
ore than 170 small GtPases have been identified as monomeric molecules of 20 to 40 kDa that bind and hydrolyze guanine nucleotides. Small GTPases in general are very important intracellular signaling proteins that control diverse cellular functions, including cell proliferation, survival and apoptosis, cell-to-cell and cell-to-extracellular matrix adhesion, cytoskeleton organization, transcriptional regulation, cell cycle progression, cell migration, cellular morphogenesis, and polarization. 1, 2 Mutant forms of small GTPases induce proliferation and transformation of a number of cell types and differentiation of neuronal cells. [3] [4] [5] Deregulation or abnormal activation of these proteins is also linked to disease processes. 6, 7 For these reasons, small GTPases represent a large class of potential drug targets that have not yet been intensively exploited by the pharmaceutical industry. 8, 9 Currently, there are limited pharmacological tools targeting individual small GTPases, and most efforts have been focused on inhibiting posttranslational GTPase modification by lipids, which is necessary for their membrane localization and activation. 10 Unfortunately, these inhibitors and drugs are not specific to GTPases and affect other cell signaling pathways, which complicate the interpretation of results and create toxicity issues. binding activities. [12] [13] [14] The fluorescence emission of BODIPYguanine nucleotides is directly affected by protein binding. Free BODIPY-nucleotides in solution exhibit quenched fluorescence, which is unquenched upon protein binding. The resulting 2-to 10-fold fluorescence enhancement allows real-time detection of protein-nucleotide interactions. We initially developed a beadbased flow cytometric, fluorescent GTP-binding assay that is highly sensitive and allows real-time measurements. 15 Here we describe the critical adaptations that enabled its application in high-throughput screening (HTS), as well as formatting for a multiplexed assay that allowed simultaneous screening of 6 GTPase targets against nearly 200,000 compounds in the Molecular Libraries Screening Center Network (MLSCN) library, resulting in the identification of small molecules that alter GTP binding to small GTPases. Multiplex bead-based flow cytometry assays allow us to simultaneously measure the activities of several small GTPases in a small volume and, for this reason, significantly reduce time and cost of HTS for multiple targets, without compromising consistency, sensitivity, or accuracy of the single-plex assay.
MATERIALS AND METHODS
Reagents and cell lines
BODIPY-FL-GTP 2'-(or-3')-O-(N-(2-aminoethyl) urethane, G-12411 and ProLong
 Gold antifade reagent were purchased from Invitrogen Molecular Probes (Eugene, OR). A colorimetric G-LISA assay kit for quantifying Rac1/2/3 activation, rhodamine phalloidin, anti-Rac1 mAb, and glutathione-S-transferase (GST)-GTPases, including wild type (wt) Cdc42, Rac1, RhoA, and H-Ras and constitutively active mutants Cdc42Q61L, Rac1Q61L, RhoAQ63L, and H-RasG12V, were purchased from Cytoskeleton, Inc. (Denver, CO). GST-Rab2, GST-Rab7 were purified as described. 15 GST-PAK-PBD and plasmids for GST-Rac1 and Rac2 were generously provided by Dr. G. 
Bokoch (Scripps Research Institute
MULTIPLExED PRIMARY SCREENS
For multiplex analysis of small GTPases, we used 4-mm diameter glutathione-beads (GSH-beads) distinguished by 7 different intensities of red color (various magnitude of emission at 665 ± 10 nm with excitation at 635 nm). Each polystyrene bead set is supplied at 1.4 × 10 5 beads/mL with about 1.2 × 10 6 glutathione sites per bead (determined by using GSTgreen fluorescent protein [GFP] ). In preparation for protein binding, 240 to 250 mL of each bead set was individually blocked with 0.1% bovine serum albumin (BSA) in buffer NP-HPS (0.01% [vol/vol] NP-40, 30 mM HEPES pH 7.5, 100 mM KCl, 20 mM NaCl) containing 1 mM EDTA (NP-HPSE) for 30 min at room temperature. Bead sets were collected by centrifugation, resuspended in 100 mL NP-HPSE, and individually incubated with 1 mM of a given GST-GTPase (Rab2 wt, Rab7 wt, Cdc42 wt, H-Ras wt, Rac1 wt, and Rac1Q61L mutant) overnight at 4 °C. Individual GTPase-coupled beads were washed twice with 100 mL ice-cold NP-HPSE buffer supplemented with 0.1% BSA and 1 mM dithiothreitol (DTT) and kept in separate tubes on ice. GTPase-coupled beads were pooled together immediately prior to loading of 5 mL of this mixture in each well of the assay plates. Next, 0.1 mL of the test compounds (1 mM stock in DMSO) was added to individual wells to give a final concentration of 10 mM compound and 1% DMSO, after which 5 mL BODIPY-FL-GTP (200 nM stock in NP-HPSE) was added to each well. Positive controls, containing the bead mixture, 0.1 mL DMSO (1% final), and fluorescent GTP, were included in columns 1 and 2 on each plate. Negative controls, containing the bead mixture with fluorescent GTP, 0.5 mM unlabeled GTP as a competitor, and 1% DMSO, were assayed separately. Each well contained approximately 2000 beads, coupled with individual GTPases. The assay was performed with 100 nM BODIPY-FL-GTP, which has a K d range of 10 to 30 nM for the G-proteins. Because the assay was performed at 3-to 10-fold the K d , 50% inhibition could be observed with small molecules at a concentration of 10 mM, which is 3-to 10-fold the K d values (i.e., 1-3 mM K d ). Based on the Z' values, a threshold inhibition of ~20% could be detected from small molecules with K d values in the 2-to 6-mM range. Plates were placed on rotators and incubated for 40 to 45 min at 4 °C. Sample analysis was conducted with a HyperCyt  high-throughput flow cytometry platform as described previously. 16 Flow cytometric light scatter and fluorescence emission at 530 ± 20 nm (FL1) and 665 ± 10 nm (FL8) were collected on a Cyan ADP flow cytometer (Beckman Coulter, Fullerton, CA). Screening of one 384-well plate takes ~15 min, and complete library screening can be performed in 8 weeks. The resulting time-dependent data (1 file per plate) were analyzed using IDLQuery software to determine the compound activity in each well. Gating based on forward scatter (FS) and side scatter (SS) parameters was used to identify singlet bead populations. Gating based on FL8 emission distinguishes the beads coated with different proteins, and the median fluorescence per bead population was calculated. A compound was considered a "potential active" if the change in activity was greater then 20% from baseline. Baselines were set to 100% based on measurements from the 1% DMSO containing positive controls as further described in PubChem. 17 
Dose-response measurements
Test compounds identified for further analysis after the primary screen were cherry-picked from compound storage plates, then serially diluted 1:3 a total of 8 times from a starting concentration of 10 mM, giving a 9-point dilution series in DMSO. The final concentrations in the assay ranged from 10 nM to 100 mM. Beads were coated with proteins as described under the Multiplexed Primary Screens section. For dose-response analyses, we used 1 multiplex (Rab7 wt, Rab2 wt, H-Ras wt, H-RasG12V, Cdc42 wt, and Cdc42Q61L) and 3 single-plexes (for Rac1 wt, Rac1Q61L, and GST-GFP).
In experiments including magnesium, we used NP-HPS buffer containing 1 mM MgCl 2 . Eight GST-GTPases were assayed simultaneously in a single multiplex (Rac1 wt, Rac1Q61L, Rac2 wt, RhoA wt and RhoAL63, Cdc42 wt, Cdc42Q61L and Ral wt), and 100 nM BODIPY-FL-GTP binding was measured in the presence or absence of the serial drug dilution series. Each dose-response series was run in triplicate.
Kinetic assays
Wild-type GST-Cdc42 (4 mM) was bound to GSH-beads overnight at 4 °C. Cdc42 on GSH-beads was depleted of nucleotide by incubating with 10 mM EDTA containing buffer for 20 min at 30 °C, washing twice with NP-HPS buffer, then resuspending in the same buffer containing 1 mM EDTA, 1 mM DTT, and 0.1% BSA. Kinetic assays were performed by incubating 50 mL of GST-Cdc42-GSH-bead suspension for 2 min with either DMSO (1% final concentration) or 10 mM MLS000532223 and subsequently adding 50 mL of various concentrations of icecold BODIPY-FL-GTP. Association of the fluorescent nucleotide was measured using a FacSCAN flow cytometer in the kinetic mode. The average number of events was 150 per s. Data were converted to ASCII format using IDLQuery (software available free from the authors). Raw data were exported and plotted using GraphPad Prism software.
Rac activation assay
Swiss 3T3 cells were used to monitor Rac1 inhibition by MLS000532223 in a cell-based assay. Cells were serum starved overnight and treated with 1% DMSO (negative control) or 10 mM compound in DMSO (1% final concentration) for 20 to 30 min. As a positive control, cells were treated with 10 ng/mL epidermal growth factor (EGF) for 2 min. Cell lysis, immunoprecipitation of active Rac1 with GST-PAK-PBD immobilized on GSH beads, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and immunoblotting were performed as described. 
G-LISA assay for active Rac
Swiss 3T3 cells were cultured and starved following standard procedures (Cytoskeleton, Inc., Denver, CO). Individual cultures grown in 6-well dishes were incubated with MLS000532223 over a concentration range from 0.1 to 10 mM for 1 h and subsequently stimulated for 2 min with 10 ng/mL EGF. Cells were washed with ice-cold phosphatebuffered saline (PBS) containing calcium and magnesium and further processed for protein and G-LISA assays. Positive controls included Rac1-GTP provided in the kit and cell lysate prepared from control cells stimulated only with EGF. Negative controls included buffer-only controls and cell lysates prepared from control cells after serum starvation.
Live-cell microscopy
Live-cell microscopy was carried out on RBL-2H3 cells. Cells were grown on coverslips overnight, washed, and overlaid with Tyrode's buffer (10 mM HEPES [pH 7.4], 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl 2 , 1 mM MgCl 2 , 5.6 mM glucose, and 0.1% BSA). Time-lapse images were taken after addition of 10 mM MLS000532223 (final concentration) at 60-s intervals for up to 100 min at 37 °C. For ligand stimulation, IgE-primed RBL cells were treated with 1 mg/mL 2,4-dinitrophenol (DNP)-BSA. Imaging was performed using a Bio-Rad Radiance 2100 confocal microscope equipped with a 60 × 1.4 NA oil immersion objective equipped with Lasersharp3000 software.
Immunofluorescence staining and microscopy
RBL-2H3 cells were grown on coverslips and cultured overnight in the presence or absence of 10 mM MLS000532223. As a positive control, cells were stimulated with 1 mg/mL DNP-BSA for 30 min as previously described. 19 Cells were washed with PBS, fixed with 3% paraformaldehyde, permeabilized for 5 min with 0.1% Triton X-100 in Tyrode's buffer, blocked for 1 h with 1% BSA in Tyrode's buffer, and stained for 1 h with rhodamine-phalloidin. All incubations were at room temperature. For imaging, samples were mounted on glass slides using ProLong  Gold antifade reagent. A Zeiss LSM 510 microscope, 40× objective, was used to collect images.
β-hexosaminidase secretion measurements
For measurement of b-hexosaminidase release, cells were cultured overnight with IgE in 24-well culture plates. IgE primed cells were washed and incubated for 1 h, with indicated concentrations of inhibitor in Tyrode's buffer. Aliquots (100 mL) of the cell culture supernatants were analyzed for the spontaneous release of b-hexosaminidase. Cells were activated by exposure to DNP-BSA (1 mg/mL) in Tyrode's buffer for 30 min at 37 °C. Release of b-hexosaminidase was determined as described in Ortega et al. 20 The values were expressed as a percentage of the total amount of b-hexosaminidase, determined using 1% Triton X-100 in Tyrode's buffer.
RESULTS
Identification and verification of Rho family GTPase inhibitors using multiplex screens
For detection of GTP binding to small GTPases, we used a flow cytometry-based assay for multiplex analysis of GTPase activity in an HTS of the MLSCN library. In the primary screen, each well of the microplate contained 7 sets of beads, with variable red fluorescence intensities. Six individual GST-GTPases representative of Rho, Ras, and Rab branches of the Ras-related GTPase family (Cdc42wt, Rac1wt, Rac1Q61L, Rab2 wt, Rab7wt, and H-Ras wt) were first bound to beads of a particular fluorescence intensity (Fig. 1A-C) . One bead set consisted of GSHbeads without any bound protein and served as a "scavenger" for GST-proteins that might dissociate during the assay and precluded cross-contamination of protein-bound bead sets. The individually conjugated beads were mixed, dispensed into 384-well plates, and incubated with fluorescent GTP in the presence of each test compound. Positive and negative controls contained DMSO at an identical concentration as wells containing test compounds. Protein-bound fluorescence served as the readout and was measured using a HyperCyt flow cytometry system. 21 Briefly, the HyperCyt has an autosampler connected to a peristaltic pump. The autosampler sips ~2 mL of suspension from each well of a multiwell plate, leaving an air gap between samples to allow individual samples to be distinguished in the flow cytometer readout. Approximately 150 to 300 beads were counted for each GTPase in each 2-mL sample. When the bead count was below 25 for a given GTPase, the result for that protein was considered "missing." For the 194,738 total compounds screened against Cdc42 wt, there were only 66 missing compounds. Figure 1D shows the time-dependent data from one 384-well plate with a single hit out of 320 test compounds on the plate. The decrease in fluorescence suggested the molecule was an inhibitor.
Primary screening of the MLSCN library (194,738 compounds) in a 6-plex system resulted in the identification of 100 to 500 positive compounds for each target protein. The complete results from the multiplex screen are available on PubChem 17 (AID 757-761 and 764). The quality control Z' statistics were very good for each target. In particular, the average Z' was 0.87 ± 0.04 for Cdc42, 0.85 ± 0.04 for Rac1 wt, and 0.90 ± 0.03 for Rac1Q61L.
The primary screening results using the described bead-based multiplex method are presented for 2 representative assay plates (Fig. 1E,F) . In the first sample plate, only 1 compound out of 320 had an inhibitory effect on BODIPY-FL-GTP binding to the tested GTPases (Fig. 1E, arrow) . Analysis of the raw flow cytometric data, made with IDLeQuery software and imported into an Excel template, revealed that the inhibitory compound was MLS000532223 (1-(3-nitrophenyl)-3-phenyl-2-propyn-1-one). The primary screening data for a second sample plate (Fig. 1F ) revealed 1 autofluorescent compound as judged by the increase in fluorescence measured for scavenger and all GTPase bead sets (arrow head), as well as a Cdc42-specific inhibitor (arrow). The Cdc42 inhibitor was identified as
Multiplex and single-plex dose-response assays were used to confirm the primary screen data. A GST-GFP control was used to eliminate the possibility of compound effects on the association of GST-proteins with the beads. Dose-response results are summarized in Table 1 Table 1 and PubChem AID 1333-1337, 1339-1341).
17 MLS000532223 behaved as a high-affinity selective inhibitor of Rho family GTPases (EC 50 1.6 × 10 ; Fig. 2B) , confirming the primary screen findings. To measure the activities of MLS000532223 and MLS000573151 on RhoA and related members of the Rho GTPase family, we conducted the multiplex assay in the presence of Mg 2+ ions, which is crucial for BODIPY-FL-GTP binding to RhoA (Fig. 2C,D) . The 8-plex consisted of wild-type and constitutively active mutants of the Rho family GTPases, including Rac1, Rac 2, RhoA, and Cdc42. Ral GTPase was included on account of the known interactions between Ral and Rho family GTPases. 22 MLS000532223 inhibited the activity of all tested GTPases of the Rho and Ral families (Fig. 2C) , whereas MLS000573151 was a specific for Cdc42 (Fig. 2D) . Thus, using flow cytometry measurements for multiplex HTS, we identified novel inhibitors with micromolar affinities for the Rho-family GTPases.
MLS000532223 modulates Rho-family GTP-binding kinetics
Real-time assays of GTP-binding kinetics in the presence or absence of MLS000532223 were performed using wildtype Cdc42 and our established flow cytometry-based assay 15 ( Fig. 3A,B) . Assays were performed holding the inhibitor concentration constant at 10 mM and monitoring kinetics of BODIPY-GTP binding over a >10-fold concentration range (6.5-200 nM GTP). The presence of the small-molecule inhibitor decreased the B max of GTP binding, whereas the affinity of GTP to wild-type Cdc42 remained constant (K d = 43 nM; Fig. 3C ). The raw data were parsed in IDLeQuery to produce annotated fluorescence summary data for each well. The parsed data were then processed through an Excel template file constructed specifically for the assay to segregate data for each target and the fluorescence scavenger in the multiplex. Only 1 compound out of 320 inhibits all GTPases (arrow). (F) The Excel file shows 1 fluorescent compound (arrow head) and 1 Cdc42-specific inhibitor (arrow).
MLS000532223 inhibits actin rearrangements and changes in cell morphology that are downstream of Rho family GTPase activation
GTPases play a key role in actin reorganization and morphological transformations of the cell. It is known that Rac1 promotes polymerization at the leading edge, orchestrating the formation of lamellipodia and membrane ruffles, 25 whereas Cdc42 and Rho are responsible for filopodia and stress fiber formations, respectively. 26 To assess if MLS000532223 might also affect downstream pathways regulated by Rho-family GTPases, we examined the effect of the compound on cell morphology and actin reorganization in RBL-2H3 cells following IgE receptor activation. This cell line has been widely used as a model for studies on hypersensitivity diseases that include allergy, asthma, and anaphylaxis. Activation of RBL cells via crosslinking of the high-affinity IgE receptor (Fc e RI) initiates cascades of biochemical events, leading to degranulation, membrane ruffling, and other physiological responses. 27 Cells begin to flatten within 2 min, spread on their substratum, and extend lamellipodia, an indicator of active ruffling. 27, 28 At later stages of activation, cells secrete inflammatory mediators. 28 The Rho family GTPases, Rac and Cdc42, are key mediators of the actin rearrangements and morphologic changes resulting from IgE receptor stimulation of RBL cells. 29, 30 We examined the actin cytoskeleton in resting, ligandstimulated, and MLS000532223 (10-mM) treated RBL cells. Staining of fixed cells with rhodamine-phalloidin and confocal microscopy were used to detect the changes in cell shape, as well as reorganization of F-actin (Fig. 5A) . Resting RBL cells were round and tall or modestly spread on the adherent growing surface (DMSO). Activation of RBL cells by cross-linking of Fc e RI caused a remarkable transformation in cell surface topography (DNP-BSA), and the cell height decreased compared to DMSO controls. Cells lost their spherical shape and became spread and elongated on the substratum, with actin becoming localized to the cell perimeter, leading edge, and surface ruffles. MLS000532223-treated cells appeared round and tall, like resting RBL cells, and failed to flatten after crosslinking of IgE receptors (MLS000532223 ± DNP-BSA).
Stress fiber formation is a hallmark of Rho activation and has been well documented in EGF-treated fibroblasts such as Swiss 3T3 cells. 25 Quiescent, serum-starved Swiss 3T3 fibroblasts exhibit filamentous actin staining largely at the cell periphery, corresponding to the cortical actin (Fig. 5B,  DMSO) . Treatment of cells with EGF activates Rho and leads to the robust formation of numerous stress fibers within 5 to 10 min after stimulation (EGF). Brief pretreatment of cells for 30 min with 10 mM MLS000532223 completely inhibited formation of stress fibers upon EGF stimulation (MLS000532223 ± EGF). 
MLS000532223 is active in cell-based assays and inhibits EGF-stimulated Rac 1 activation
Serum-starved Swiss 3T3 cells were used to monitor Rac1 activation in the presence or absence of 10 mM MLS000532223 using a serine/threonine p-21 activated kinase (PAK) binding assay (Fig. 4A) . This method takes advantage of the fact that only the active GTP-bound form of Rac is capable of binding to the PBD domain of PAK. 18 The low level of active Rac1 in DMSO-treated (negative control) cells (lane 2) was completely abolished after a 30-min pretreatment of cells with 10 mM MLS000532223 (lane 3). Cells treated with 10 ng/mL EGF for 2 min showed a robust activation of Rac1 (lane 5), whereas growth factor-induced activation of Rac1 was completely inhibited by preliminary treatment of starved cells with 10 mM MLS000532223 (lane 4).
In vitro measurements of BODIPY-FL-GTP binding to GSTRac1, immobilized on beads, showed that the inhibitory effects of 10 mM MLS000532223 and 50 mM NSC23766 (a known Rac inhibitor 23 ) were similar, suggesting greater efficacy of MLS000532223. There was no inhibition of GTP binding to Rac1 in the presence of 10 mM EHT1864 (selective inhibitor of Rac GTPases in fibroblasts 24 ; Fig. 4B ). An enzyme-linked immunosorbent assay (ELISA) for Rac1 activation was used to monitor the dose-dependent inhibition of EGF-mediated Rac activation. Cells were pretreated with varying concentrations of MLS000532223 prior to a 2-min exposure to EGF and comparatively evaluated against NSC23766. MLS000532223 effectively inhibited EGF-stimulated activation of Rac1 at 3 to 10 mM, whereas NSC23766 showed more modest inhibition even at doses up to 50 mM. Neither compound was effective at blocking EGF-stimulated Rac activation at concentrations of 1 mM or less (Fig. 4C) . Live-cell imaging studies were used to monitor the dynamic responses to MLS000532223 in real time. Cross-linking of IgE receptors induced cell flattening, ruffling, and formation of lamellipodia and filopodia within a minute after stimulation, and surface ridges were enhanced after 15 to 20 min (Fig. 6B) , as compared to DMSO-treated cells, which remained spherical (Fig. 6A) . The presence of 10 mM MLS000532223 completely abrogated normal cell shape changes in response to ligandmediated activation (Fig. 6D) , whereas resting RBL-2H3 cells treated with MLS000532223 showed no change in morphology (Fig. 6C) .
Thus, in 2 different cell lines, actin rearrangements and changes in cell morphology in response to receptor-mediated activation of Rho family GTPases were completely abrogated. The data confirm that MLS000532223 acts on upstream Rho family GTPase targets (Rac1, Cdc42, and RhoA) and thereby broadly inhibits downstream responses such as lamellipodia, filopodia, and stress fiber formation as expected.
NSC23766 and EHT1864 were recently reported to selectively inhibit Rac GTPases in fibroblasts. 23, 31 Therefore, it was of interest to compare available inhibitors to MLS000532223 in the hematopoietic cells studied here. In contrast to MLS000532223, 10 mM EHT1864 failed to inhibit RBL-2H3 cell shape changes and b-hexosaminidase secretion in response to ligand stimulation (Fig. 6E, Fig. 7A ). NSC23766 was toxic for RBL-2H3 cells, inducing extensive b-hexosaminidase spontaneous release and cell death (Fig. 7A) . The data suggest that different Rac inhibitors may exhibit cell type specificity, which should be carefully evaluated.
DISCUSSION
For detection of GTP binding to small GTPases, we used a flow cytometry-based assay. 15 This method was found to be very sensitive (it can detect GTP binding activity using ~140 pM bead-bound protein or approximately 1.4 fmol of protein per 10-mL reaction) and allowed us to measure a dose response of GTP binding to individual GST-tagged small GTPases even though different conditions were required for optimal activity of individual GTPases. BODIPY-GTPgNH was identified as a better substrate for some of the small GTPases such as RhoA wt, Rac1wt, and Cdc42, whereas others (Rab proteins 15 and Ras) preferred binding to BODIPY-FL-GTP. Mg 2+ ions were crucial for Rho enzyme activity measurement, whereas Rab proteins and H-Ras more effectively bound fluorescent GTP in the presence of EDTA. Activity of H-Ras was completely inhibited in the presence of 0.01% dodecyl maltoside in the assay, whereas this detergent had a negligible effect on GTP binding by other GTPases. On the basis of these preliminary results, we chose specific conditions, which, although not optimal for all GTPases, allowed us to simultaneously measure GTP binding of several small GTPases. Experiments comparing GTP binding to individual GTPases in the multiplex or single-plex assay format were identical, and therefore a multiplex flow cytometric assay was used for HTS of an MLSCN library. Approximately 200,000 compounds were screened for identification of potential activators and inhibitors of GTP binding to 6 different small GTPases. This approach allowed us to collect and analyze more than 1.2 million data points in the primary screen. A total of 100 to 500 positive compounds for each member of the multiplex were identified in the primary screen (the results from this multiplex screen were published on PubChem AID 757-761, 764). False positives such as autofluorescent compounds and compounds affecting GST-protein binding to GSH-beads were eliminated, and ~1200 compounds were selected and tested in secondary dose-response assays, of which 18% of the compounds judged to be active in the primary screen were confirmed in dose-response analysis. Here we identified Rho family-selective (MLS000532223) and Cdc42-specific (MLS000573151) inhibitors and characterized the cellular activity of MLS000532223 in detail. The pull-down assay of 
MLS000532223 inhibits ligand-stimulated β-hexosaminidase release
In RBL-2H3 cells, ligand-stimulated activation of Fc e RI and Rho family GTPases stimulates both actin remodeling and b-hexosaminidase secretion. Therefore, the compound was also tested for an ability to affect b-hexosaminidase secretion in resting and stimulated RBL-2H3 cells. In the absence of ligand stimulation, there was no b-hexosaminidase secretion with the 10-mM MLS000532223 compound (Fig. 7A) , indicating that the compound is not toxic to cells. In ligand-stimulated cells, the presence of 10 mM MLS000532223 reduced secretion by 50% (Fig. 7B) .
active Rac1 showed that MLS000532223 completely inhibited EGF-induced Rac1 activation in Swiss 3T3 cells. Live-cell imaging and confocal microscopy studies demonstrated the inhibition of actin reorganization and cell morphology changes downstream of Rho family GTPase activation.
Inhibitors of Rho family GTPases are of significant interest as targets for drug therapy. Hyperactivated small GTPases are implicated in 30% of all human cancers and are particularly prevalent in myeloid leukemia and pancreatic, lung, and colon carcinomas. 4, 5 Rho family GTPases have been found central to the control of gene regulation, cell proliferation, and cell migration. 2 Thus, it is not surprising that based on overexpression or hyperactivation, they are increasingly associated with cancer cell metastasis and invasion, as well as uncontrolled proliferation and loss of growth control. 32 Based on the inhibitory activity of MLS000532223 on Rac1, Rac2, and Cdc42 in hematopoietic cell types, it will be of interest to further develop this probe for possible use to control the growth of leukemic cells.
Kinetic experiments revealed that MLS000532223 did not affect the K d of GTP binding, and because its activity was not reversible (data not shown), this suggests that it is not a competitive inhibitor for the GTP binding site. The observed incomplete inhibition of GTP binding could represent an allosteric binding site, limited molecular solubility, or protein heterogeneity, which has not been resolved by the experiments performed to date.
Comparison of MLS000532223 against 2 other Rac1-specific inhibitors that have been developed, NSC23766 and EHT1864, reveals the importance of biological context. 23, 31 NSC23766 was developed using a rational drug design and was found to specifically inhibit guanine nucleotide exchange and Rac1 activation without affecting Cdc42 or RhoA both in vitro and in cell-based assays. 23 At the doses (50 mM) used on NIH 3T3 cells, NSC23766 proved toxic to RBL-2H3 cells, and at lower doses (10 mM), it failed to inhibit the activated FceR1-induced cell spreading and lamellipodia formation. EHT1864, identified as an inhibitor of amyloid precursor processing, interacts with Rac1 and related isoforms. Although EHT1864 blocked lamellipodia formation in NIH 3T3 fibroblasts following plateletderived growth factor stimulation, 31 as shown here, it did not block activated FceR1-induced cell spreading and ruffling in RBL-2H3 cells. Together, the data suggest that MLS000532223 is an effective Rho GTPase inhibitor for hematopoietic cells and that cell-type-specific inhibition of Rho family GTPases may be possible and a worthwhile therapeutic strategy.
In sum, our data indicate that a multiplex bead-based assay could successfully be used via flow cytometry for HTS of libraries. This is a low-cost, time-saving, and highly efficient method for the simultaneous measurements of the activity for the number of proteins. Moreover, it enabled the analysis, comparison, and detection of the specific activators/inhibitors of individual GTPases in a systematic and previously unparalleled manner. The identified small molecules provide a new chemical platform for the rational design of selective inhibitors of key small G-protein members that could represent a boon for understanding the biology and pharmacology of small GTPases.
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